Neximmune announces data showing aim act t cells enhance the response to bispecific t cell engager therapy at the 2023 tandem meetings: transplantation & cellular therapy meetings of astct and cibmtr

Gaithersburg, md., feb. 16, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced that new positive, preclinical data will be presented in an abstract titled “prior antigen exposure enhances the t cell response to bispecific t cell engager therapy” at the 2023 tandem meetings: transplantation & cellular therapy meetings of astct and cibmtr, taking place on february 15-19, 2023 in orlando, florida.
NEXI Ratings Summary
NEXI Quant Ranking